AU2009236290A1 - Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS - Google Patents

Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS Download PDF

Info

Publication number
AU2009236290A1
AU2009236290A1 AU2009236290A AU2009236290A AU2009236290A1 AU 2009236290 A1 AU2009236290 A1 AU 2009236290A1 AU 2009236290 A AU2009236290 A AU 2009236290A AU 2009236290 A AU2009236290 A AU 2009236290A AU 2009236290 A1 AU2009236290 A1 AU 2009236290A1
Authority
AU
Australia
Prior art keywords
posaconazole
hpmcas
composition
polymer
azole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009236290A
Other languages
English (en)
Inventor
Larry Yun Fang
David Harris
Jiansheng Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2009236290A1 publication Critical patent/AU2009236290A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: SCHERING CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2009236290A 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS Abandoned AU2009236290A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045,177 2008-04-15
PCT/US2009/040653 WO2009129301A2 (en) 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a molecular solid dispersion

Publications (1)

Publication Number Publication Date
AU2009236290A1 true AU2009236290A1 (en) 2009-10-22

Family

ID=41165581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009236290A Abandoned AU2009236290A1 (en) 2008-04-15 2009-04-15 Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS

Country Status (6)

Country Link
US (1) US20110034478A1 (enExample)
EP (1) EP2278957A2 (enExample)
JP (1) JP2011516613A (enExample)
AU (1) AU2009236290A1 (enExample)
CA (1) CA2720851A1 (enExample)
WO (1) WO2009129301A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
US9493582B2 (en) 2012-02-28 2016-11-15 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
HK1213585A1 (zh) 2012-10-22 2016-07-08 Cydex Pharmaceuticals, Inc. 烷基化环糊精组合物及其制备和使用方法
WO2014196519A1 (ja) 2013-06-03 2014-12-11 信越化学工業株式会社 加熱溶融押出用組成物及びこれを用いた加熱溶融押出成型物の製造方法
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
EP3183295B1 (en) 2014-08-22 2023-08-02 CyDex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
AU2015348043B2 (en) 2014-11-21 2019-08-22 F2G Limited Antifungal agents
US11058682B2 (en) * 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP3925601B1 (en) 2016-02-26 2024-07-17 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) * 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
WO2020159562A1 (en) 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
WO2022034232A1 (en) 2020-08-13 2022-02-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
AU2022324717A1 (en) 2021-11-25 2024-06-13 Alfred E. Tiefenbacher (Gmbh Und Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN117545470A (zh) * 2023-09-18 2024-02-09 北京德立福瑞医药科技有限公司 泊沙康唑固体分散体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
US5790957A (en) * 1995-09-12 1998-08-04 Nokia Mobile Phones Ltd. Speech recall in cellular telephone
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
TR200003598T2 (tr) * 1998-03-26 2001-06-21 Japan Tobacco Inc. Amid türevleri ve nosiseptin antagonistleri
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
BR0208626A (pt) * 2001-04-03 2004-03-09 Schering Corp Composição antifúngica com biodisponibilidade intensificada
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Also Published As

Publication number Publication date
EP2278957A2 (en) 2011-02-02
WO2009129301A3 (en) 2009-12-23
CA2720851A1 (en) 2009-10-22
WO2009129301A2 (en) 2009-10-22
US20110034478A1 (en) 2011-02-10
JP2011516613A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
US20110034478A1 (en) Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs
US20110002989A1 (en) Methods, dosage forms and kits for administering ziprasidone without food
JP2025134801A (ja) オラパリブの溶解度及び生体利用効率が改善された組成物
EP2323631A1 (en) Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
EP4037659B1 (en) Pharmaceutical composition comprising enzalutamide
CA2916143A1 (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
CN114126712A (zh) 无定形司巴森坦（sparsentan）组合物
WO2009129297A1 (en) Semi-solid oral pharmaceutical compositions
JP5635491B2 (ja) 固形医薬組成物
US20230310393A1 (en) Sorafenib pharmaceutical composition with high bioavailability and use thereof
US9968607B2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
WO2024095137A1 (en) Pharmaceutical composition of empagliflozin and process thereof
JP2025512818A (ja) 可溶化したブラジキニンｂ２受容体アンタゴニストを含む固体組成物
US20100317642A1 (en) Pharmaceutical composition of orlistat
US12465565B2 (en) Pharmaceutical compositions of raltegravir
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
WO2026019402A1 (en) A pharmaceutical composition comprising nanosuspension of canagliflozin
WO2026019401A1 (en) A nanosuspension composition comprising canagliflozin
EP4661846A1 (en) Milvexian pharmaceutical compositions
WO2025144121A1 (en) Empagliflozin composition with independent dissolution profile
WO2023038600A1 (en) A capsule formulation comprising macitentan
EP4398910A1 (en) A capsule formulation comprising macitentan
WO2023080854A1 (en) Lurasidone hydrochloride compositions

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application